{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T16:51:13Z","timestamp":1789750273528,"version":"4.0.1"},"reference-count":22,"publisher":"American Society for Microbiology","issue":"3","license":[{"start":{"date-parts":[[2023,3,23]],"date-time":"2023-03-23T00:00:00Z","timestamp":1679529600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2023,3,23]],"date-time":"2023-03-23T00:00:00Z","timestamp":1679529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["J Clin Microbiol"],"published-print":{"date-parts":[[2023,3,23]]},"abstract":"<jats:p>Eravacycline (ERV) (brand name Xerava [Tetraphase]) is a new tetracycline-class antibacterial that has been approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for treatment of complicated intra-abdominal infections (cIAIs).<\/jats:p>","DOI":"10.1128\/jcm.01650-22","type":"journal-article","created":{"date-parts":[[2023,3,6]],"date-time":"2023-03-06T14:09:36Z","timestamp":1678111776000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":12,"title":["Multicenter Clinical Evaluation of ETEST Eravacycline for Susceptibility Testing of\n            <i>Enterobacteriaceae<\/i>\n            and Enterococci"],"prefix":"10.1128","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5087-7500","authenticated-orcid":true,"given":"Laurine S.","family":"Blanchard","sequence":"first","affiliation":[{"name":"bioM\u00e9rieux, SA, Marcy l\u2019Etoile, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas P.","family":"Armstrong","sequence":"additional","affiliation":[{"name":"bioM\u00e9rieux Inc., Hazelwood, Missouri, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Kresken","sequence":"additional","affiliation":[{"name":"Antiinfectives Intelligence, GmbH, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher L.","family":"Emery","sequence":"additional","affiliation":[{"name":"Indiana University School of Medicine, Indianapolis, Indiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun X.","family":"Ying","sequence":"additional","affiliation":[{"name":"Quest Diagnostics, Lewisville, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Sauvonnet","sequence":"additional","affiliation":[{"name":"bioM\u00e9rieux, SA, La Balme-les-Grottes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Zambardi","sequence":"additional","affiliation":[{"name":"bioM\u00e9rieux, SA, La Balme-les-Grottes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.106178"},{"key":"e_1_3_2_3_2","volume-title":"XERAVA (eravacycline) for injection, for intravenous use package insert.","author":"Tetraphase Pharmaceuticals","year":"2018","unstructured":"Tetraphase Pharmaceuticals. 2018. XERAVA (eravacycline) for injection, for intravenous use package insert. Tetraphase Pharmaceuticals, La Jolla, CA. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/211109lbl.pdf."},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/ja.2016.73"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04809-14"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.106215"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2021.106353"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00797-20"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2022.05.020"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2021.10.020"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-020-00351-0"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-021-01735-1"},{"key":"e_1_3_2_13_2","unstructured":"Food and Drug Administration. 2019. FDA clearance K192050 (Regulation Number: 21 CFR 866.1640). https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfpmn\/pmn.cfm?ID=K192050."},{"key":"e_1_3_2_14_2","unstructured":"Food and Drug Administration. 2022. FDA-recognized antimicrobial susceptibility test interpretive criteria. https:\/\/www.fda.gov\/drugs\/development-resources\/fda-recognized-antimicrobial-susceptibility-test-interpretive-criteria."},{"key":"e_1_3_2_15_2","volume-title":"Performance standards for antimicrobial susceptibility testing","author":"Clinical and Laboratory Standards Institute","year":"2019","unstructured":"Clinical and Laboratory Standards Institute. 2019. Performance standards for antimicrobial susceptibility testing, 29th ed. M100. Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"29"},{"key":"e_1_3_2_16_2","volume-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically","author":"Clinical and Laboratory Standards Institute","year":"2018","unstructured":"Clinical and Laboratory Standards Institute. 2018. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 11th ed. M07. Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"11"},{"key":"e_1_3_2_17_2","unstructured":"International Standards Organization. 2019. ISO 20776-1:2019: susceptibility testing of infectious agents and evaluation of performance of antimicrobial susceptibility test devices\u2014part 1: broth micro-dilution reference method for testing the in vitro activity of antimicrobial agents against rapidly growing aerobic bacteria involved in infectious diseases. https:\/\/www.iso.org\/standard\/70464.html."},{"key":"e_1_3_2_18_2","volume-title":"Guidance for industry and FDA: class II special controls guidance document: antimicrobial susceptibility test (AST) systems.","author":"Food and Drug Administration","year":"2009","unstructured":"Food and Drug Administration. 2009. Guidance for industry and FDA: class II special controls guidance document: antimicrobial susceptibility test (AST) systems. Food and Drug Administration, Rockville, MD. https:\/\/www.fda.gov\/media\/88069\/download."},{"key":"e_1_3_2_19_2","unstructured":"International Standards Organization. 2007. ISO 20776-2:2007: clinical laboratory testing and in vitro diagnostic test systems\u2014susceptibility testing of infectious agents and evaluation of performance of antimicrobial susceptibility test devices\u2014part 2: evaluation of performance of antimicrobial susceptibility test devices. https:\/\/www.iso.org\/standard\/41631.html."},{"key":"e_1_3_2_20_2","unstructured":"EUCAST. 2019. Routine and extended internal quality control for MIC determination and disk diffusion as recommended by EUCAST v9.0. https:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/QC\/v_9.0_EUCAST_QC_tables_routine_and_extended_QC.pdf."},{"key":"e_1_3_2_21_2","unstructured":"EUCAST. 2019. Breakpoint tables for interpretation of MICs and zone diameters v9. https:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Breakpoint_tables\/v_9.0_Breakpoint_Tables.pdf."},{"key":"e_1_3_2_22_2","unstructured":"Food and Drug Administration. 2015. Response to STMA request for changes to the document titled Guidance for Industry and FDA Class II Special Controls Guidance Document: Antimicrobial Susceptibility Test (AST) Systems."},{"key":"e_1_3_2_23_2","unstructured":"Food and Drug Administration Susceptibility Testing Manufacturers Association. 2017. Antimicrobial susceptibility testing meeting."}],"container-title":["Journal of Clinical Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/jcm.01650-22","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/jcm.01650-22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,23]],"date-time":"2023-03-23T13:02:39Z","timestamp":1679576559000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/jcm.01650-22"}},"subtitle":[],"editor":[{"given":"Erin","family":"McElvania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2023,3,23]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3,23]]}},"alternative-id":["10.1128\/jcm.01650-22"],"URL":"https:\/\/doi.org\/10.1128\/jcm.01650-22","relation":{},"ISSN":["0095-1137","1098-660X"],"issn-type":[{"value":"0095-1137","type":"print"},{"value":"1098-660X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,23]]},"assertion":[{"value":"2022-11-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-10","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-06","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01650-22"}}